The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback